Review



rabbit anti mbl c antibody  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rabbit anti mbl c antibody
    Rabbit Anti Mbl C Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti mbl c antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    rabbit anti mbl c antibody - by Bioz Stars, 2025-05
    93/100 stars

    Images



    Similar Products

    93
    Hycult Biotech rabbit anti mbl c antibody
    Rabbit Anti Mbl C Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti mbl c antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    rabbit anti mbl c antibody - by Bioz Stars, 2025-05
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech 14d12
    14d12, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/14d12/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    14d12 - by Bioz Stars, 2025-05
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech rat anti mbl c
    Rat Anti Mbl C, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mbl c/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    rat anti mbl c - by Bioz Stars, 2025-05
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech rat antimbl c
    Rat Antimbl C, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat antimbl c/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    rat antimbl c - by Bioz Stars, 2025-05
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech rat anti mouse mbl c monoclonal antibody
    Activity of anti-fibrinogen mAb glycovariants in complement activation. (A) Schematic depiction of different glycan chains linked to asparagine 297 (Asn297) of the CH2 domain of IgG heavy chain. Gal, galactose; GLcNAc, N-acetyl glucosamine; man, mannose. (B) Blotting with Erythrina cristagalli lectin (ECL) detects the level of terminal galactosylation. Coomassie blue-stained gel is shown for protein loading control. (C) Mouse serum (as a source <t>of</t> <t>MBL,</t> at the indicated percentage of dilution) was incubated with plate-bound C9 or G10 mAb (10 μg/mL); <t>MBL-C</t> binding to the mAb was detected with an anti–MBL-C antibody. Data shown represent mean ± SEM of triplicate values derived from three independent experiments. *P < 0.01, **P < 0.001. (D) Aortas from elastase-perfused, G10-reconstituted μMT mice were probed for MBL-C (blue) and G10 (red) deposition. Representative sections showing colocalization of MBL-C and fibrinogen (detected with G10 mAb). Elastic fibers (EF) autofluoresce in green and blue spectra. (Scale bar, 15 μm.) (E) μMT mice were perfused with elastase and immediately injected with 250 μg of isotype control or the indicated mAb. Aortas were harvested at 30 min and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (F) Quantitative analysis of MBL-C binding and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype (iso) control (set at 1). *P < 0.05, **P < 0.01, ***P < 0.002, NS, not significant.
    Rat Anti Mouse Mbl C Monoclonal Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse mbl c monoclonal antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    rat anti mouse mbl c monoclonal antibody - by Bioz Stars, 2025-05
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech rat anti mouse mbl c
    Activity of anti-fibrinogen mAb glycovariants in complement activation. (A) Schematic depiction of different glycan chains linked to asparagine 297 (Asn297) of the CH2 domain of IgG heavy chain. Gal, galactose; GLcNAc, N-acetyl glucosamine; man, mannose. (B) Blotting with Erythrina cristagalli lectin (ECL) detects the level of terminal galactosylation. Coomassie blue-stained gel is shown for protein loading control. (C) Mouse serum (as a source of MBL, at the indicated percentage of dilution) was incubated with plate-bound C9 <t>or</t> <t>G10</t> mAb (10 μg/mL); <t>MBL-C</t> binding to the mAb was detected with an anti–MBL-C antibody. Data shown represent mean ± SEM of triplicate values derived from three independent experiments. *P < 0.01, **P < 0.001. (D) Aortas from elastase-perfused, G10-reconstituted μMT mice were probed for MBL-C (blue) and G10 (red) deposition. Representative sections showing colocalization of MBL-C and fibrinogen (detected with G10 mAb). Elastic fibers (EF) autofluoresce in green and blue spectra. (Scale bar, 15 μm.) (E) μMT mice were perfused with elastase and immediately injected with 250 μg of isotype control or the indicated mAb. Aortas were harvested at 30 min and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (F) Quantitative analysis of MBL-C binding and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype (iso) control (set at 1). *P < 0.05, **P < 0.01, ***P < 0.002, NS, not significant.
    Rat Anti Mouse Mbl C, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse mbl c/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    rat anti mouse mbl c - by Bioz Stars, 2025-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    Activity of anti-fibrinogen mAb glycovariants in complement activation. (A) Schematic depiction of different glycan chains linked to asparagine 297 (Asn297) of the CH2 domain of IgG heavy chain. Gal, galactose; GLcNAc, N-acetyl glucosamine; man, mannose. (B) Blotting with Erythrina cristagalli lectin (ECL) detects the level of terminal galactosylation. Coomassie blue-stained gel is shown for protein loading control. (C) Mouse serum (as a source of MBL, at the indicated percentage of dilution) was incubated with plate-bound C9 or G10 mAb (10 μg/mL); MBL-C binding to the mAb was detected with an anti–MBL-C antibody. Data shown represent mean ± SEM of triplicate values derived from three independent experiments. *P < 0.01, **P < 0.001. (D) Aortas from elastase-perfused, G10-reconstituted μMT mice were probed for MBL-C (blue) and G10 (red) deposition. Representative sections showing colocalization of MBL-C and fibrinogen (detected with G10 mAb). Elastic fibers (EF) autofluoresce in green and blue spectra. (Scale bar, 15 μm.) (E) μMT mice were perfused with elastase and immediately injected with 250 μg of isotype control or the indicated mAb. Aortas were harvested at 30 min and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (F) Quantitative analysis of MBL-C binding and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype (iso) control (set at 1). *P < 0.05, **P < 0.01, ***P < 0.002, NS, not significant.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation

    doi: 10.1073/pnas.1315512110

    Figure Lengend Snippet: Activity of anti-fibrinogen mAb glycovariants in complement activation. (A) Schematic depiction of different glycan chains linked to asparagine 297 (Asn297) of the CH2 domain of IgG heavy chain. Gal, galactose; GLcNAc, N-acetyl glucosamine; man, mannose. (B) Blotting with Erythrina cristagalli lectin (ECL) detects the level of terminal galactosylation. Coomassie blue-stained gel is shown for protein loading control. (C) Mouse serum (as a source of MBL, at the indicated percentage of dilution) was incubated with plate-bound C9 or G10 mAb (10 μg/mL); MBL-C binding to the mAb was detected with an anti–MBL-C antibody. Data shown represent mean ± SEM of triplicate values derived from three independent experiments. *P < 0.01, **P < 0.001. (D) Aortas from elastase-perfused, G10-reconstituted μMT mice were probed for MBL-C (blue) and G10 (red) deposition. Representative sections showing colocalization of MBL-C and fibrinogen (detected with G10 mAb). Elastic fibers (EF) autofluoresce in green and blue spectra. (Scale bar, 15 μm.) (E) μMT mice were perfused with elastase and immediately injected with 250 μg of isotype control or the indicated mAb. Aortas were harvested at 30 min and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (F) Quantitative analysis of MBL-C binding and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype (iso) control (set at 1). *P < 0.05, **P < 0.01, ***P < 0.002, NS, not significant.

    Article Snippet: After washes, the plates were incubated with rat anti-mouse MBL-C monoclonal antibody (0.4 μg/mL; HM 1038, clone 14D12; Hycult Biotech) followed by incubation with anti-rat-HRP (0.16 μg/mL; 112-035-167; Jackson ImmunoResearch Laboratories).

    Techniques: Activity Assay, Activation Assay, Staining, Incubation, Binding Assay, Derivative Assay, Injection

    Effect of galactose removal on C9 mAb activity. (A) Untreated and β-galactosidase–treated C9 mAbs were blotted with Erythrina cristagalli lectin (ECL) to confirm depletion of terminal galactose residues in C9(G0). Coomassie blue-stained gel is shown for loading control. (B) Binding of MBL-C to untreated C9 and galactose-depleted C9(G0) mAb. Data shown represent mean ± SEM of triplicate values derived from two independent experiments. *P < 0.01. (C) μMT mice were perfused with elastase and administered 250 μg of C9 or C9(G0) mAb i.v. At 30 min, aortas were harvested and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (D) Quantitative analysis of MBL-C and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype control (set at 1). *P = 0.0089, **P = 0.0008. Pathogenicity of C9(G0) mAb in μMT mice. (E) Day 14 AD, expressed as percentage, in WT, untreated or μMT mice treated i.v. with 250 μg of the indicated mAb. Values represent mean ± SEM; each symbol represents an individual mouse. *P < 0.01, **P < 0.001, NS, not significant.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation

    doi: 10.1073/pnas.1315512110

    Figure Lengend Snippet: Effect of galactose removal on C9 mAb activity. (A) Untreated and β-galactosidase–treated C9 mAbs were blotted with Erythrina cristagalli lectin (ECL) to confirm depletion of terminal galactose residues in C9(G0). Coomassie blue-stained gel is shown for loading control. (B) Binding of MBL-C to untreated C9 and galactose-depleted C9(G0) mAb. Data shown represent mean ± SEM of triplicate values derived from two independent experiments. *P < 0.01. (C) μMT mice were perfused with elastase and administered 250 μg of C9 or C9(G0) mAb i.v. At 30 min, aortas were harvested and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (D) Quantitative analysis of MBL-C and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype control (set at 1). *P = 0.0089, **P = 0.0008. Pathogenicity of C9(G0) mAb in μMT mice. (E) Day 14 AD, expressed as percentage, in WT, untreated or μMT mice treated i.v. with 250 μg of the indicated mAb. Values represent mean ± SEM; each symbol represents an individual mouse. *P < 0.01, **P < 0.001, NS, not significant.

    Article Snippet: After washes, the plates were incubated with rat anti-mouse MBL-C monoclonal antibody (0.4 μg/mL; HM 1038, clone 14D12; Hycult Biotech) followed by incubation with anti-rat-HRP (0.16 μg/mL; 112-035-167; Jackson ImmunoResearch Laboratories).

    Techniques: Activity Assay, Staining, Binding Assay, Derivative Assay, Activation Assay

    The LP contribution to elastase-induced AAA. (A) Mice were perfused with elastase on day 0 and day 14. AD was measured and expressed as increase in percentage (%). Mice deficient in MBL-A and MBL-C (MBL-A/C−/−) were as resistant to elastase-induced AAA as the AP factor B-deficient (fB−/−) mice. Each symbol represents an individual mouse. Values represent mean ± SEM *P < 0.001; NS, not significant. (B) IgG (red) binding to elastase-perfused aorta is independent of MBL-A/C. In contrast, there was minimal properdin (red) deposition in MBL-A/C−/− perfused aorta, whereas properdin was found in abundance in WT perfused aorta. Armenian hamster IgG served as isotype control for anti-properdin mAb (H4). (Scale bar, 50 μM.) (C) Quantitative analysis of properdin deposition in abdominal aortas 30 min after elastase perfusion. n = 3 aortas per genoytpe, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM in WT compared with MBL-A/C−/− (set at 1). *P = 0.0004. (D) Schematic of the order of events in murine elastase-induced AAA. Elastase perfusion triggers local injury, inducing fibrinolysis/fibrin clot formation and revealing neoepitopes that are recognized by natural antibodies. MBL binds antibodies and the immune complex initiates LP activation and properdin-stabilized convertase (C3bBbP) assembly, with subsequent amplification by the AP. Complement activation leads to the generation of anaphylatoxins (C3a, C5a) that attract neutrophils, setting up the inflammatory cascade and culminating in the eventual aneurysmal development.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation

    doi: 10.1073/pnas.1315512110

    Figure Lengend Snippet: The LP contribution to elastase-induced AAA. (A) Mice were perfused with elastase on day 0 and day 14. AD was measured and expressed as increase in percentage (%). Mice deficient in MBL-A and MBL-C (MBL-A/C−/−) were as resistant to elastase-induced AAA as the AP factor B-deficient (fB−/−) mice. Each symbol represents an individual mouse. Values represent mean ± SEM *P < 0.001; NS, not significant. (B) IgG (red) binding to elastase-perfused aorta is independent of MBL-A/C. In contrast, there was minimal properdin (red) deposition in MBL-A/C−/− perfused aorta, whereas properdin was found in abundance in WT perfused aorta. Armenian hamster IgG served as isotype control for anti-properdin mAb (H4). (Scale bar, 50 μM.) (C) Quantitative analysis of properdin deposition in abdominal aortas 30 min after elastase perfusion. n = 3 aortas per genoytpe, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM in WT compared with MBL-A/C−/− (set at 1). *P = 0.0004. (D) Schematic of the order of events in murine elastase-induced AAA. Elastase perfusion triggers local injury, inducing fibrinolysis/fibrin clot formation and revealing neoepitopes that are recognized by natural antibodies. MBL binds antibodies and the immune complex initiates LP activation and properdin-stabilized convertase (C3bBbP) assembly, with subsequent amplification by the AP. Complement activation leads to the generation of anaphylatoxins (C3a, C5a) that attract neutrophils, setting up the inflammatory cascade and culminating in the eventual aneurysmal development.

    Article Snippet: After washes, the plates were incubated with rat anti-mouse MBL-C monoclonal antibody (0.4 μg/mL; HM 1038, clone 14D12; Hycult Biotech) followed by incubation with anti-rat-HRP (0.16 μg/mL; 112-035-167; Jackson ImmunoResearch Laboratories).

    Techniques: Binding Assay, Activation Assay, Amplification

    Activity of anti-fibrinogen mAb glycovariants in complement activation. (A) Schematic depiction of different glycan chains linked to asparagine 297 (Asn297) of the CH2 domain of IgG heavy chain. Gal, galactose; GLcNAc, N-acetyl glucosamine; man, mannose. (B) Blotting with Erythrina cristagalli lectin (ECL) detects the level of terminal galactosylation. Coomassie blue-stained gel is shown for protein loading control. (C) Mouse serum (as a source of MBL, at the indicated percentage of dilution) was incubated with plate-bound C9 or G10 mAb (10 μg/mL); MBL-C binding to the mAb was detected with an anti–MBL-C antibody. Data shown represent mean ± SEM of triplicate values derived from three independent experiments. *P < 0.01, **P < 0.001. (D) Aortas from elastase-perfused, G10-reconstituted μMT mice were probed for MBL-C (blue) and G10 (red) deposition. Representative sections showing colocalization of MBL-C and fibrinogen (detected with G10 mAb). Elastic fibers (EF) autofluoresce in green and blue spectra. (Scale bar, 15 μm.) (E) μMT mice were perfused with elastase and immediately injected with 250 μg of isotype control or the indicated mAb. Aortas were harvested at 30 min and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (F) Quantitative analysis of MBL-C binding and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype (iso) control (set at 1). *P < 0.05, **P < 0.01, ***P < 0.002, NS, not significant.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation

    doi: 10.1073/pnas.1315512110

    Figure Lengend Snippet: Activity of anti-fibrinogen mAb glycovariants in complement activation. (A) Schematic depiction of different glycan chains linked to asparagine 297 (Asn297) of the CH2 domain of IgG heavy chain. Gal, galactose; GLcNAc, N-acetyl glucosamine; man, mannose. (B) Blotting with Erythrina cristagalli lectin (ECL) detects the level of terminal galactosylation. Coomassie blue-stained gel is shown for protein loading control. (C) Mouse serum (as a source of MBL, at the indicated percentage of dilution) was incubated with plate-bound C9 or G10 mAb (10 μg/mL); MBL-C binding to the mAb was detected with an anti–MBL-C antibody. Data shown represent mean ± SEM of triplicate values derived from three independent experiments. *P < 0.01, **P < 0.001. (D) Aortas from elastase-perfused, G10-reconstituted μMT mice were probed for MBL-C (blue) and G10 (red) deposition. Representative sections showing colocalization of MBL-C and fibrinogen (detected with G10 mAb). Elastic fibers (EF) autofluoresce in green and blue spectra. (Scale bar, 15 μm.) (E) μMT mice were perfused with elastase and immediately injected with 250 μg of isotype control or the indicated mAb. Aortas were harvested at 30 min and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (F) Quantitative analysis of MBL-C binding and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype (iso) control (set at 1). *P < 0.05, **P < 0.01, ***P < 0.002, NS, not significant.

    Article Snippet: Frozen cross-sections of mouse abdominal aortic tissues were fixed in acetone, blocked in 8% BSA in PBS, and incubated with G10 mAb (2 μg/mL), rat anti-mouse MBL-C (2 μg/mL; HM 1038, clone 14D2; Hycult Biotech), goat anti-mouse C3 (8 μg/mL; 55463; MP Biomedicals), hamster anti-mouse properdin mAb (6 μg/mL, clone H4 generated in house by D.E.H. and P.B.) ( Fig. S4 ), Armenian hamster IgG isoptype control (6 μg/mL; I-140; Leinco Technologies) or rabbit anti-mouse fibrinogen (10 μg/mL; ab34269; Abcam) for 1 h at RT followed by the appropriate fluorescent-conjugated secondary antibody (Jackson ImmunoResearch Laboratories).

    Techniques: Activity Assay, Activation Assay, Staining, Incubation, Binding Assay, Derivative Assay, Injection

    Effect of galactose removal on C9 mAb activity. (A) Untreated and β-galactosidase–treated C9 mAbs were blotted with Erythrina cristagalli lectin (ECL) to confirm depletion of terminal galactose residues in C9(G0). Coomassie blue-stained gel is shown for loading control. (B) Binding of MBL-C to untreated C9 and galactose-depleted C9(G0) mAb. Data shown represent mean ± SEM of triplicate values derived from two independent experiments. *P < 0.01. (C) μMT mice were perfused with elastase and administered 250 μg of C9 or C9(G0) mAb i.v. At 30 min, aortas were harvested and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (D) Quantitative analysis of MBL-C and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype control (set at 1). *P = 0.0089, **P = 0.0008. Pathogenicity of C9(G0) mAb in μMT mice. (E) Day 14 AD, expressed as percentage, in WT, untreated or μMT mice treated i.v. with 250 μg of the indicated mAb. Values represent mean ± SEM; each symbol represents an individual mouse. *P < 0.01, **P < 0.001, NS, not significant.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation

    doi: 10.1073/pnas.1315512110

    Figure Lengend Snippet: Effect of galactose removal on C9 mAb activity. (A) Untreated and β-galactosidase–treated C9 mAbs were blotted with Erythrina cristagalli lectin (ECL) to confirm depletion of terminal galactose residues in C9(G0). Coomassie blue-stained gel is shown for loading control. (B) Binding of MBL-C to untreated C9 and galactose-depleted C9(G0) mAb. Data shown represent mean ± SEM of triplicate values derived from two independent experiments. *P < 0.01. (C) μMT mice were perfused with elastase and administered 250 μg of C9 or C9(G0) mAb i.v. At 30 min, aortas were harvested and examined for MBL-C (red) or C3 (red) deposition as evidence of complement activation. Representative photomicrographs are shown. (Scale bar, 50 μm.) (D) Quantitative analysis of MBL-C and C3 deposition in abdominal aortas 30 min after elastase perfusion and mAb transfer. n = 3 aortas per treatment, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM compared with isotype control (set at 1). *P = 0.0089, **P = 0.0008. Pathogenicity of C9(G0) mAb in μMT mice. (E) Day 14 AD, expressed as percentage, in WT, untreated or μMT mice treated i.v. with 250 μg of the indicated mAb. Values represent mean ± SEM; each symbol represents an individual mouse. *P < 0.01, **P < 0.001, NS, not significant.

    Article Snippet: Frozen cross-sections of mouse abdominal aortic tissues were fixed in acetone, blocked in 8% BSA in PBS, and incubated with G10 mAb (2 μg/mL), rat anti-mouse MBL-C (2 μg/mL; HM 1038, clone 14D2; Hycult Biotech), goat anti-mouse C3 (8 μg/mL; 55463; MP Biomedicals), hamster anti-mouse properdin mAb (6 μg/mL, clone H4 generated in house by D.E.H. and P.B.) ( Fig. S4 ), Armenian hamster IgG isoptype control (6 μg/mL; I-140; Leinco Technologies) or rabbit anti-mouse fibrinogen (10 μg/mL; ab34269; Abcam) for 1 h at RT followed by the appropriate fluorescent-conjugated secondary antibody (Jackson ImmunoResearch Laboratories).

    Techniques: Activity Assay, Staining, Binding Assay, Derivative Assay, Activation Assay

    The LP contribution to elastase-induced AAA. (A) Mice were perfused with elastase on day 0 and day 14. AD was measured and expressed as increase in percentage (%). Mice deficient in MBL-A and MBL-C (MBL-A/C−/−) were as resistant to elastase-induced AAA as the AP factor B-deficient (fB−/−) mice. Each symbol represents an individual mouse. Values represent mean ± SEM *P < 0.001; NS, not significant. (B) IgG (red) binding to elastase-perfused aorta is independent of MBL-A/C. In contrast, there was minimal properdin (red) deposition in MBL-A/C−/− perfused aorta, whereas properdin was found in abundance in WT perfused aorta. Armenian hamster IgG served as isotype control for anti-properdin mAb (H4). (Scale bar, 50 μM.) (C) Quantitative analysis of properdin deposition in abdominal aortas 30 min after elastase perfusion. n = 3 aortas per genoytpe, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM in WT compared with MBL-A/C−/− (set at 1). *P = 0.0004. (D) Schematic of the order of events in murine elastase-induced AAA. Elastase perfusion triggers local injury, inducing fibrinolysis/fibrin clot formation and revealing neoepitopes that are recognized by natural antibodies. MBL binds antibodies and the immune complex initiates LP activation and properdin-stabilized convertase (C3bBbP) assembly, with subsequent amplification by the AP. Complement activation leads to the generation of anaphylatoxins (C3a, C5a) that attract neutrophils, setting up the inflammatory cascade and culminating in the eventual aneurysmal development.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation

    doi: 10.1073/pnas.1315512110

    Figure Lengend Snippet: The LP contribution to elastase-induced AAA. (A) Mice were perfused with elastase on day 0 and day 14. AD was measured and expressed as increase in percentage (%). Mice deficient in MBL-A and MBL-C (MBL-A/C−/−) were as resistant to elastase-induced AAA as the AP factor B-deficient (fB−/−) mice. Each symbol represents an individual mouse. Values represent mean ± SEM *P < 0.001; NS, not significant. (B) IgG (red) binding to elastase-perfused aorta is independent of MBL-A/C. In contrast, there was minimal properdin (red) deposition in MBL-A/C−/− perfused aorta, whereas properdin was found in abundance in WT perfused aorta. Armenian hamster IgG served as isotype control for anti-properdin mAb (H4). (Scale bar, 50 μM.) (C) Quantitative analysis of properdin deposition in abdominal aortas 30 min after elastase perfusion. n = 3 aortas per genoytpe, six to nine sections per aorta. Values represent fold increase in integrated OD (IntDen) ± SEM in WT compared with MBL-A/C−/− (set at 1). *P = 0.0004. (D) Schematic of the order of events in murine elastase-induced AAA. Elastase perfusion triggers local injury, inducing fibrinolysis/fibrin clot formation and revealing neoepitopes that are recognized by natural antibodies. MBL binds antibodies and the immune complex initiates LP activation and properdin-stabilized convertase (C3bBbP) assembly, with subsequent amplification by the AP. Complement activation leads to the generation of anaphylatoxins (C3a, C5a) that attract neutrophils, setting up the inflammatory cascade and culminating in the eventual aneurysmal development.

    Article Snippet: Frozen cross-sections of mouse abdominal aortic tissues were fixed in acetone, blocked in 8% BSA in PBS, and incubated with G10 mAb (2 μg/mL), rat anti-mouse MBL-C (2 μg/mL; HM 1038, clone 14D2; Hycult Biotech), goat anti-mouse C3 (8 μg/mL; 55463; MP Biomedicals), hamster anti-mouse properdin mAb (6 μg/mL, clone H4 generated in house by D.E.H. and P.B.) ( Fig. S4 ), Armenian hamster IgG isoptype control (6 μg/mL; I-140; Leinco Technologies) or rabbit anti-mouse fibrinogen (10 μg/mL; ab34269; Abcam) for 1 h at RT followed by the appropriate fluorescent-conjugated secondary antibody (Jackson ImmunoResearch Laboratories).

    Techniques: Binding Assay, Activation Assay, Amplification